GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells toward Breast Tumor Progression.

Maria Francesca Santolla, Adele Vivacqua, Rosamaria Lappano, Damiano Cosimo Rigiracciolo, Francesca Cirillo, Giulia Raffaella Galli, Marianna Talia, Giuseppe Brunetti, Anna Maria Miglietta, Antonino Belfiore, Marcello Maggiolini

Journal: Cells 2019;8(3):223

PMID: 30866584

Abstract

The FGF2/FGFR1 paracrine loop is involved in the cross-talk between breast cancer cells and components of the tumor stroma as cancer-associated fibroblasts (CAFs). By quantitative PCR (qPCR), western blot, immunofluorescence analysis, ELISA and ChIP assays, we demonstrated that 17β-estradiol (E2) and the G protein estrogen receptor (GPER) agonist G-1 induce the up-regulation and secretion of FGF2 via GPER together with the EGFR/ERK/c-fos/AP-1 signaling cascade in (ER)-negative primary CAFs. Evaluating the genetic alterations from METABRIC and TCGA datasets, we then assessed that FGFR1 is the most frequently amplified FGFRs family member and its amplification/expression associates with shorter survival rates in breast cancer patients. Therefore, in order to assess the functional FGF2/FGFR1 interplay between CAFs and breast cancer cells, we generated the FGFR1-knockout MDA-MB-231 cells using CRISPR/Cas9 genome editing strategy. Using conditioned medium from estrogen-stimulated CAFs, we established that the activation of FGF2/FGFR1 paracrine signaling triggers the expression of the connective tissue growth factor (CTGF), leading to the migration and invasion of MDA-MB-231 cells. Our findings shed new light on the role elicited by estrogens through GPER in the activation of the FGF2/FGFR1 signaling. Moreover, our findings may identify further biological targets that could be considered in innovative combination strategies halting breast cancer progression.

Address: Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. [email protected].; Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. [email protected].; Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. [email protected].; Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. [email protected].; Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. [email protected].; Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. [email protected].; Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. [email protected].; University of Natural Resources and Life Sciences, 1180 Vienna, Austria. [email protected].; Regional Hospital, 87100 Cosenza, Italy. [email protected].; Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, 95122 Catania, Italy. [email protected].; Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.